Schema-Root.org logo

 

  cross-referenced news and research resources about

 Mylan Pharmaceuticals, Inc

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Mon. January 8, 2024

-
Mylan said it plans to launch two new HIV treatments in the U.S. at a significant discount to competing products. The combination tablets are Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate or TDF) and Cimduo (lamivudine and TDF). Mylan has been selling Symfi Lo overseas since March ...

Vermont Labor Commissioner Lindsay Kurrle said she learned from a displaced Mylan worker who went to the department's career resource center in St. Albans that the company cut about 30 upper management jobs. The giant pharmaceutical company, based in Canonsburg, Pennsylvania, declined to ...
Mylan N.V. MYL, +0.69% said Friday it is planning to launch two new low-cost HIV combination treatments in the U.S. The company said Symfi Lo and Cimduo won U.S. Food and Drug Administration approval in February. Symfi Lo will be introduced in the coming weeks and Cimduo will be launched in the ...
During 2017, Mylan repurchased approximately 12.4 million shares for approximately $500.2 million under its previously approved share repurchase program. In January 2018, Mylan bought back additional ordinary shares worth 9.8 million for approximately $432.0 million and completed that share ...
Mylan announced its fourth-quarter and full-year 2017 results after the market closed on Wednesday. Did the company meet its expectations? It did. And while there were still some weak spots, the drugmaker's performance improved from the third quarter. Here are the highlights from Mylan's fourth-quarter ...
Mylan NV shares surged on Thursday after the company announced plans to bring a lower-priced biosimilar version of the bestselling cosmetic treatment Botox to market. The biosimilar, a collaboration with Revance Therapeutics Inc. RVNC, +4.86% would allow Mylan to vie for one of rival Allergan's AGN, ...
Shares of Mylan NV MYL, +0.69% fell less than 1% late Wednesday after the pharmaceutical company reported better-than-expected adjusted per-share earnings but sales that fell short of expectations. Mylan said it earned $244 million, or 46 cents a share, in the quarter, compared with $418 million, or 78 ...
Competitive environment in the U.S. generic market is causing deflation and reduced profitability. However, the market is rationalizing capacity. Recent Mylan acquisitions have diversified its product portfolio away from U.S. generics into a global specialty company providing durable cash flows. Near-term ...


 

news and opinion


 


 


 


 


schema-root.org

     mylan
       epipen

pharmaceutical industry:
     allergan
     ariad
     astrazeneca
     baxter
     eli lilly
     glaxosmithkline
     merck
     mylan
     novartis
     pfizer
     products
     purdue pharma
     research
     takeda
     teva
     upjohn
     valeant